secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001193125-24-051759
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron shareholders approve 3M share increase for equity plan, authorize 100M common shares
--------------------------------------------------------------------------------

- Stockholders approved conversion of Series X Convertible Preferred into common; pro forma shares outstanding ~29.5M.
- Authorized common shares increased from 45M to 100M via certificate of amendment effective Feb 28, 2024.
- 2021 Stock Incentive Plan amended to add 3,000,000 shares; compensation vote advisory '1 Year' frequency adopted.
- Three Class III directors elected (Alves-Aivado, Ambros, von Rickenbach) to three-year terms.
- Anticipated automatic conversion of ~12,087 Series X shares into 12,087,075 common shares on March 5, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524051759/0001193125-24-051759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524051759/d802393d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-051759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer